This is a preview of subscription content, log in via an institution to check access.
References
Arpaillange, P., Gaston-Mathé, J. L.: Therapeutic trials and the applicable principles of law. Biomedicine 28, 57 (1978)
Breast Cancer Task Force Treatment Committee: National Cancer Institute Report from the Combination Chemotherapy Trials Working Group, p. 10 DHEW Publication No. (NIH) 77-1192: DHEW 1977
Borck, N., Hohorst, H. J.: Metabolism of cyclophosphamide. Cancer 20, 900 (1967)
Carter, S. K.: Study design principles for the clinical evaluation of new drugs as developed by the chemotherapy programme of the NCI. In: The design of clinical trials in cancer therapy. Staquet, M. (ed.), p. 242. Bruxelles: Sc. Europ. 1972
Chen, H. S. G., Gross, J. F.: Physiologically based pharmacokinetic models for anticancer drugs. Cancer Chemother. Pharmacol. 2, 85 (1979)
Colloque International sur les Animaux de Laboratoire, Lyon, Septembre 1978
Dantchev, D., Slioussartchouk, V., Paintrand, M., Hayat, M., Bourut, C., Mathé, G.: Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with adriamycin, detorubicin, AD-32 and aclacinomycin. Cancer Treat. Rep. 63, 875 (1979)
Dayan, A. D.: Uses and limitations of primates in the evaluation of drug efficacy and safety. J. R. Soc. Med. 71, 691 (1978)
EORTC Clinical Screening Group: Proposal for the introduction of uniformity in the expression of evaluation criteria in therapeutic responses. EORTC Newsletter no 29, 1973
Hayat, M., Bourut, C., Chenu, E., Montero, J. L., Imbach, J. L., MacDonald, J. S., Mathé, G.: Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin. I. Oncostatic effects in mice. Cancer Chemother. Pharmacol. (in press, 1979)
Homan, E. R.: Quantitative relationship between toxic doses of antitumor chemotherapeutic agents in animals and man. Cancer Chemother. Rep. 3 (3), 13 (1972)
Imbach, J. L., Montero, J. L., Moruzzi, A., Serrou, B., Chenu, E., Hayat, M., Mathé, G.: The oncostatic and immunosuppressive action of new nitrosourea derivatives containing sugar radicals. Biomedicine 23, 410 (1975)
Lortat-Jacob, J. L., Mathé, G., Servier, J. (eds.): Proceedings of the International Meeting on Comparative Therapeutic Trials, Paris, January 1978. Biomedicine 28, special issue (1978)
Mathé, G.: Les essais thérapeutiques cliniques. Bull. Cancer 61, 191 (1974)
Mathé, G., Kenis, Y.: Logistics of therapeutic trials: the example of cancerology. Biomedicine 18, 181 (1973)
NCOG: Proposed NCOG response criteria. S. K. Carter (Pers. comm.)
Penta, J. S., Rozencweig, M., Guarino, A. M., Muggia, F. M.: Mouse and large animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trials. Cancer Chemother. Pharmacol. 3, 97 (1979)
Ribaud, P., Alcock, N., Burchenal, J. H., Young, C., Muggia, F., Mathé, G.: Preclinical trial in baboon and phase I–II trials and pharmacokinetics in man of malonato-platinum (MP). Proc. Am. Soc. Clin. Oncol. 20, 336 (Abstract C-186) (1979)
Schepartz, S. A.: Screening. Cancer Chemother. Rep. 2, 3 (1971)
UICC: TNM, Classification of malignant tumors, 2nd ed., Geneva: WHO 1974
WHO/EORTC/NCI: Meeting on standardization of reporting of results of cancer treatment
WHO: International Histological Classification of Tumors. 13 vol. Geneva: WHO 1967–1975
Zahardo, D. S.: Pharmacokinetics. Cancer Chemother. Rep. 3 (3), 21 (1972)
Author information
Authors and Affiliations
Additional information
French-American Cooperation NCI-INSERM
Rights and permissions
About this article
Cite this article
Ribaud, P., Mathé, G. Phase I trials in clinical oncostatic pharmacology. Cancer Chemother. Pharmacol. 4, 1–3 (1980). https://doi.org/10.1007/BF00255450
Issue Date:
DOI: https://doi.org/10.1007/BF00255450